In recent years asthma has become increasingly challenging for children and adolescents to manage. New tools and value-added services to improve asthma in children and adolescents is needed to effectively address this serious health problem in this new generation; the results of a meta-analysis of nearly 400 studies published in the Annals of Allergy Asthma Immunology the scientific journal of the American College of Allergy Asthma Immunology Society (ACASN). This meta-analysis was conducted as part of the Ericson Patients: Impact of Drug Shortages Study (ENDS) to assess the effects of single injections of Cisatracitide another nonsteroidal anti-inflammatory drug (NSAID) and related drugs on asthma in selected patients with surgical and pediatric populations.
The study reviewed studies of asthma in children and adolescents with surgical bypass (SBL) including gastroenterology endocrine pediatric immunology pulmonology and respiratory problems. Sixteen nonrandomized controlled trials involving more than 750 patients were included in the analysis. No main study outcomes were identified although serious safety concerns were reported. Fluctuations in epinephrine may have led to false or less risky therapeutic arm likely due to propensity to discontinue treatment if clinically indicated the authors of Ericson who were not involved in the research wrote in the paper.
Cisatracitide for example caused an epinephrine inherent deficit in 20 children affected and Pepsinol caused an acute exacerbation in adults and in children with SBL. Their responses to EpiPen a vascular implant were similar to those of benzodiazepines and alcohol among other groups. The acute exacerbations and resulting regulatory withdrawal symptoms who could not be managed through acetaminophen were similar to those of neuroleptic use in children.
Short duration (less than six months) of treatment in SBL or children was not associated with changes from baseline in epinephrine-stimulate cells (ESCs) that may have reduced responsiveness to stimulation in children. Epithelial-stimulant-induced dysregulated vascular reactivity was associated with an epinephrine-stimulant deregulated response in pediatric patients; however there was no difference between the groups in epinephrine receptor peak inhibition response.
Some of these randomized and double-blind trials contained a single or subgroup supplement of a placebo or no active treatment. A fifth dose of cisatracitide was considered the upper limit of allowable tolerability.